Johnson & Johnson (ETR: JNJ)
Germany
· Delayed Price · Currency is EUR
138.94
-0.18 (-0.13%)
Dec 20, 2024, 5:35 PM CET
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $22.47B USD in the quarter ending September 29, 2024, with 5.25% growth. This brings the company's revenue in the last twelve months to $87.70B, up 4.77% year-over-year. In the year 2023, Johnson & Johnson had annual revenue of $85.16B with 6.46% growth.
Revenue (ttm)
$87.70B
Revenue Growth
+4.77%
P/S Ratio
n/a
Revenue / Employee
$664.87K
Employees
131,900
Market Cap
333.92B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
Dec 29, 2019 | 82.06B | 478.00M | 0.59% |
Dec 30, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Jan 1, 2017 | Pro | Pro | Pro |
Jan 3, 2016 | Pro | Pro | Pro |
Dec 28, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionJohnson & Johnson News
- 2 days ago - Johnson & Johnson: Dividend Legend At A Discount - Seeking Alpha
- 2 days ago - Transparency in Leadership: A Business Leader’s Double-Edged Sword - CEOWORLD magazine
- 3 days ago - Of 63 Fortune500 Industry Leaders, 57 Pay Dividends, 38 Test 'Safer' & 1 Is Ideal To Buy - Seeking Alpha
- 3 days ago - Health Rounds: J&J drug helps delay multiple myeloma in high-risk patients - Reuters
- 3 days ago - Johnson & Johnson submits application to the European Medicines Agency seeking approval of a new indication for IMBRUVICA® (ibrutinib) in adult patients with previously untreated mantle cell lymphoma (MCL) who are eligible for autologous stem cell transplant - GlobeNewsWire
- 4 days ago - Johnson & Johnson says injectable Rybrevant rejected by FDA - Seeking Alpha
- 5 days ago - J&J denied extension of patent on TB drug, to benefit patients - The Times of India
- 5 days ago - US FDA declines to approve injection form of J&J's lung cancer drug - Reuters